A recent analysis of the increasing annual total number of drug manufacturer refunds to 340B covered entities notes they are [...] …
Articles by : Rich Daly, Editor in Chief
While the Biden administration’s proposal to address drug shortages does not exempt certain drug products from 340B pricing like the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The dozens of health systems suing the federal government over the reversal of a pandemic-era 340B child site registration waiver [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drugmaker Genentech has formally issued contract pharmacy restrictions after it gave some 340B hospitals advance notice last month of its [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Active 340B contract pharmacies reached 17,250 in 2024, according to a conservative think tank using data collected by another group funded by [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drugmaker Sumitomo Pharma America (SMPA) announced it will implement first-time contract pharmacy restrictions next month. The biotech company, which is [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drugmakers Amgen and Johnson & Johnson have announced they will provide refunds to 340B providers on past purchases of multiple [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Eighty-five percent of DSH hospitals earned more in estimated 340B revenue in 2022 than they incurred in charity care costs, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal auditors determined terminations from the 340B program were required for either a covered entity site or a contract pharmacy [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A federal judge recently dismissed a large California health system’s whistleblower case against four pharmaceutical companies for alleged fraudulent 340B [...] …